In our model, neuronal dysfunction drives the changes similar to a reported mouse model of Parkinson’s disease where disruption of striatal glutamatergic innervation resulted in reduction in both GLT-1 and GLAST protein expression, accompanied by dysfunction of glutamate uptake [16, 23, 31]. This evidence concerns the gene SLC1A3 and Parkinson disease.